The Molecular Biology of Myeloma

David S. Siegel, MD, PhD

Video Categories: Targeted Therapies

Dr. David S. Siegel discusses the importance of understanding the molecular biology of myeloma. Physicians can now look at and offer alternative treatments to patients that they identify will most likely do poorly with traditional treatment. He believes this area will develop quickly over the next 2 to 5 years.
March 24, 2015

The Global Challenge of Personalized Medicines

Dr. Stainthorpe explains that when it comes to bringing personalized medicines to fruition, the challenge is the same worldwide. It is an effort that requires better understanding of disease pathways and markers as well as improved diagnostics.

July 13, 2021

Offering the Appropriate Patient the Opportunity for Treatment with TRK Inhibitors

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss who may and may not be appropriate candidates for TRK inhibitor therapy.